Jessica Livingston, cofounder of the venerated startup incubator Y Combinator, gave an interesting interview this week on some of the problems female founders continue to face in the tech world and how this is changing.
Speaking with Fortune, Livingston said that the biggest issue female founders are encountering is fund-raising, as most venture capital investors continue to be men (in another recent piece, Fortune reported that women make up less than 6 percent of people making investment decisions at venture firms in the U.S.). Lots of female founders say they’re being ignored while investors pay attention to their male cofounders, she said. Perhaps this is starting to change a bit, though, because as she also pointed out, in Y Combinator’s last two classes, startups with female founders had the two biggest Series A funding rounds.
Livingston said that 25 percent of Y Combinator’s most recent class of startups had one or more female founders on their teams (up from 4 percent in 2011); her goal, not surprisingly, is to increase this figure to 50 percent. One way she’s working on this is by holding the Female Founders Conference, which began in 2014 and gives advice to women interested in starting their own tech companies.
As for specific women she’s rooting for, Livingston mentioned Tracy Young, the CEO and a cofounder of a startup called PlanGrid, which makes cloud-based software for viewing construction plans, saying that company has the biggest valuation of any Y Combinator graduating company that is headed up by a woman.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.